What is Lucence?
Founded in 2016 and headquartered in Singapore, Lucence operates at the intersection of biotechnology and clinical diagnostics. The company develops sophisticated liquid biopsy blood tests designed to identify optimal cancer treatment pathways through comprehensive molecular profiling. By shifting the paradigm from invasive tissue biopsies to high-sensitivity blood-based assays, Lucence provides clinicians with actionable insights that improve patient outcomes. The company's market position is bolstered by its commitment to deep tech innovation, enabling it to address the critical need for accessible, accurate, and rapid diagnostic tools in the oncology landscape. As a key player in the precision medicine ecosystem, Lucence continues to refine its proprietary technology to meet the evolving demands of healthcare providers and patients worldwide.
How much funding has Lucence raised?
Lucence has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2019): $20M with participation from Lim Kaling, SGInnovate, IHH Healthcare, Heliconia Capital, and Koh Boon Hwee
Key Investors in Lucence
SGInnovate
SGInnovate is a government-backed entity dedicated to growing Singapore's Deep Tech landscape by investing in startups and nurturing talent within the sector.
Heliconia Capital
Heliconia Capital is an investment firm that focuses on growth-stage companies, providing strategic capital to help businesses scale internationally.
IHH Healthcare
IHH Healthcare is a leading international healthcare provider that invests in medical technologies to enhance clinical service delivery and patient care standards.
What's next for Lucence?
With the successful closure of this major strategic investment, Lucence is well-positioned to scale its operational footprint and expand its clinical validation studies. The company is expected to leverage this capital to enhance its R&D pipeline, focusing on the integration of artificial intelligence into its molecular analysis platforms. Furthermore, the strategic backing from prominent regional and global investors suggests a clear path toward international market penetration and the commercialization of its next-generation diagnostic suite. As the precision oncology market continues to mature, Lucence's focus on scalable, high-throughput testing will likely serve as a cornerstone for its long-term growth strategy and competitive differentiation in the global health-tech sector.
See full Lucence company page
